Table 4 Details of infections during follow-up
From: Pulmonary involvement of ANCA-associated vasculitis in adult Chinese patients
|  | Alveolar hemorrhage (n = 47) | Interstitial lung disease (n = 204) | Pulmonary granuloma (n = 54) | Airway involvement (n = 61) |
|---|---|---|---|---|
Infectious patients, no. (%) | 34 (72.3) | 105 (51.5) | 43 (79.7) | 55 (90.2)a |
First in-patient infection time, median (IQR) (weeks) | 2 (2–9) | 3 (2–17) | 3 (3–13) | 3 (2–9) |
Infectious episodes, no. (%) | 53 | 147 | 60 | 87 |
Infection pathogens, no. (%) | Â | Â | Â | Â |
Bacteria | 48/53 (90.6) | 138/147 (93.8) | 54/60 (90.0) | 82/87 (94.3) |
Fungus | 20/53 (37.7) | 38/147 (25.9) | 15/60 (25.0) | 20/87 (23.0) |
 Pneumocystis jirovecii | 0 | 8/147 (5.4) | 3/60 (5.0) | 3/87 (3.4) |
 Aspergillus | 3/53 (5.7) | 6/147 (4.1) | 6/60 (6.7) | 3/87 (3.4) |
 Candida | 12/53 (22.6) | 24/147 (16.3) | 8/60 (13.3) | 16/87 (18.4) |
Viral | 6/53 (11.3) | 17/147 (11.6) | 6/60 (10.0) | 4/87 (4.6) |
 CMV | 2/53 (3.8) | 6/147 (4.1) | 6/60 (10.0) | 1/87 (1.1) |
 EBV | 1/53 (1.9) | 4/147 (2.7) | 4/60 (6.7) | 0 |
 Influenza virus | 0 | 2/147 (1.4) | 0 | 1/87 (1.1) |
Locations of infection, no. (%) | Â | Â | Â | Â |
Pulmonary | 50/53 (94.3) | 135/147 (91.8) | 57/60 (95.0) | 85/87 (97.7) |
Genitourinary | 1/53 (1.9) | 17/147 (11.7) | 2/60 (3.3) | 7/87 (8.0) |
Gastrointestinal | 4/53 (7.5) | 5/147 (3.4) | 2/60 (3.3) | 2/87 (2.3) |
Catheter-associated | 1/53 (1.9) | 4/147 (2.7) | 1/60 (1.7) | 2/87 (2.3) |
Sepsis | 1/53 (1.9) | 8/147 (5.4) | 2/60 (3.3) | 0 |